Pfizer–BioNTech COVID-19 vaccine - Wikipedia
WEBThe Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [33] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing.
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full …
WEBDec 11, 2020 · The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to: prevent COVID-19 in individuals 12 years of age and older, and; provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine …
WEBAug 16, 2024 · In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives.
Pfizer-BioNTech COVID-19 Vaccine | FDA
WEBSep 11, 2023 · The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) is authorized for all doses administered to individuals 6 months through 11 years of age to prevent COVID-19. The Pfizer-BioNTech...
Pfizer COVID-19 Vaccine Summary | Vaccines & Immunizations
WEBAug 28, 2024 · Pfizer-BioNTech COVID-19 Vaccine is indicated for individuals 5 through 11 years of age (via a 10mcg / 0.3mL single-dose vial presentation) and for individuals 6 months through 4 years of age (via a 3mcg / 0.3mL multi-dose vial (3 doses per vial) presentation). Ordering and Return Policy. Minimum Initial Order.
Grading of Recommendations, Assessment, Development, and …
WEBAug 21, 2024 · Introduction. On August 23, 2021, the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for Pfizer-BioNTech COVID-19 Vaccine (COMIRNATY®) for the prevention of COVID-19 in individuals aged ≥16 years. 35 As part of the process employed by the Advisory Committee for Immunization Practices (ACIP), a systematic review and Grading of Recommendations ...
The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: What you …
WEBAug 18, 2022 · This article provides a summary of the interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19 issued by WHO Strategic Advisory Group of Experts on Immunization (SAGE).
FDA Approves First COVID-19 Vaccine
WEBFDA approved the first COVID-19 vaccine, which has been known as the Pfizer-BioNTech COVID-19 Vaccine, and is now marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19...
WEBAug 22, 2024 · The Pfizer-BioNTech COVID-19 Vaccine is a vaccine for use in individuals 6 months through 11 years of age to prevent COVID-19. The FDA has authorized the emergency use of the...
Pfizer and BioNTech Announce Vaccine Candidate Against …
WEBNov 9, 2020 · Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis. Analysis evaluated 94 confirmed cases of COVID-19 in trial participants.
- Some results have been removed